A plan to breed as many as 30,000 monkeys for medical research in a small Georgia town is drawing fresh attention this week after reports revealed the billionaire investor behind it: Joe Lonsdale, the co-founder of data-analytics company Palantir Technologies. His venture firm, 8VC, put $20 million into the startup behind the proposal, Safer Human Medicine, in a bet that America's drug industry needs a homegrown supply of research primates — even as regulators move to reduce animal testing and the project's flagship site remains stalled in litigation.
 |
| A long-tailed macaque, the species at the center of the proposed Georgia breeding facility. |
The story, first reported in detail by Forbes on October 27 and picked up widely in the days since, has reignited a debate that sits at the intersection of biotechnology, animal welfare, and national supply chains. Supporters describe the venture as a matter of medical security. Critics call it an industrial-scale breeding operation for intelligent, social animals — and question whether it will ever be built at all.
A $20 Million Bet on Research Monkeys
Safer Human Medicine was founded in 2023 with a single focus: breeding and supplying non-human primates for biomedical research. According to reports, the company has raised $28 million in total, with Lonsdale's 8VC accounting for most of it through a $20 million investment made in 2023.
The investment had not been widely known until recently. Lonsdale first spoke about it publicly on investor Jack Altman's podcast in May, where he called the work "pro-human" and asked: "Would you rather save your sibling or the monkey?" According to reports, 8VC wrote about Safer Human Medicine on its X account for the first time in the week before the Forbes report appeared.
"America needs a reliable domestic supply of research primates to help rapidly advance cures for our kids," Lonsdale said in a statement quoted in the reporting. "Leadership means having the courage to support research that can save lives even when it sounds controversial."
Lonsdale, 44, co-founded Palantir in 2003 with Peter Thiel and others and started 8VC in 2015. The Austin, Texas-based firm manages about $6 billion and has made large bets on defense technology and life sciences. He is reported to be worth about $3.8 billion.
Why Drug Companies Want More Monkeys
The commercial logic behind the venture rests on a genuine shortage. Long-tailed macaques are the species most widely used in testing the safety of new medicines, particularly biologics such as monoclonal antibodies, whose effects in rodents often do not reflect their effects in humans. For decades, American laboratories relied heavily on imports.
That supply has been disrupted repeatedly. China, which once supplied about 60 percent of the primates used in American biomedical research, halted exports in 2020. Laboratories turned to Cambodia, where prices rose to as much as $20,000 per animal from about $3,000 a few years before the pandemic. In late 2022, the U.S. Justice Department charged members of an alleged smuggling ring, including Cambodian wildlife officials, with bringing wild-caught monkeys into the country labeled as captive-bred, further constraining supply.
Today, most long-tailed macaques imported into the United States come from Mauritius and Vietnam, according to the Centers for Disease Control and Prevention. For drug developers, the shortage has increased costs and delayed studies. Long-duration safety studies for some monoclonal antibody programs can require more than 100 macaques, at an estimated cost of up to $50,000 per animal including study expenses.
"We refer to primates as the rare earth minerals of biotech," said Jim Harkness, the company's founder and chief executive. "Our focus is solely on primate breeding and supply chain."
Some online posts have linked the price surge to AI-driven drug research, but that connection is not confirmed in the reporting.
The Georgia Town Where the Plan Stalled
The company's larger ambition is a breeding center in Bainbridge, Georgia, a town of about 15,000 people in Decatur County in the southwest of the state. At peak capacity, the facility would hold 30,000 long-tailed macaques — at least triple the number housed at any other U.S. breeding facility, according to the Animal Welfare Institute. The plan reportedly begins with 500 to 1,000 animals sourced from Asian breeding facilities and grows toward the 30,000 mark over roughly 20 years.
In December 2023, local officials approved an incentive package that included up to $300 million in bonds, about 200 acres of land, and 10 years without property taxes. Safer Human Medicine pledged to invest $270 million and create about 263 jobs.
Residents objected, raising concerns about noise, smell, escapes, and disease, and the animal rights group People for the Ethical Treatment of Animals helped organize the opposition. "PETA urges Bainbridge officials to withdraw their support and shut down this project before a shovel hits the dirt," Lisa Jones-Engel, a senior science adviser at the group, said at the time.
In February 2024, the county development authority pulled out of the deal. Safer Human Medicine sued the authority and the county in federal court in Georgia, accusing the authority of breaking a binding contract. That case is still going on, and the company does not own the land. State courts upheld the validation of the bonds, and Georgia's Supreme Court declined to review that decision in April 2025, while separate disputes over open-meetings compliance and a nuisance claim by residents have continued.
In short, the Bainbridge facility is not operating, and no construction has begun. The company has made partial progress elsewhere: in 2025 it bought a site in LaBelle, Florida, where it holds and quarantines monkeys. That facility is operating and has lined up customers, according to reports.
 |
| Long-tailed macaques are the species most widely used in testing the safety of new medicines, according to reports. |
What This Means
The venture exposes a tension at the heart of American drug development. On one side, researchers argue that primate studies remain essential for many complex medicines, and that a domestic supply would reduce dependence on foreign governments, smuggling enforcement, and volatile prices. On the other, regulators and scientists are actively developing alternatives — computer modeling, lab-grown tissue, and organ-on-a-chip systems — that could shrink demand for primates over time.
That regulatory shift is the venture's biggest long-term risk. A 2022 U.S. law ended the requirement that new drugs be tested on animals before human trials. The Food and Drug Administration has since moved further: in April 2025 it published a roadmap to reduce animal testing in preclinical safety studies, starting with monoclonal antibodies, one of the largest categories of primate use. In December 2025 it issued draft guidance setting out when six-month primate toxicity studies for certain antibody programs could be reduced or eliminated, and in April 2026 it reported meeting its first-year goals for broader acceptance of new testing methods.
The agency argues that animal studies are poor predictors of human outcomes, noting that about 90 percent of drugs that pass animal testing still fail in humans. Scientists caution, however, that alternatives cannot yet replace animal studies for many complex drugs. "Cutting corners on safety and efficacy assessments is never going to be a good thing to do for society," said Kenneth Ramos, a professor of medical sciences at Texas A&M University.
The company's leadership history adds a reputational dimension. Harkness was previously chief operating officer of Envigo, a research-animal supplier whose Virginia beagle-breeding facility was shut down in 2022 after federal inspectors documented serious welfare violations. Envigo's parent company, Inotiv, later pleaded guilty and agreed to pay $35 million in fines and settlements. Harkness left Envigo in 2022 and was never charged; he has declined to comment on the matter. Opponents of the Georgia facility have cited that history.
 |
| A researcher at work in a biomedical laboratory. Drug developers say primate studies remain necessary for many complex medicines. |
What Happens Next
Over the next 12 to 24 months, several developments will determine whether the venture advances or stalls further. The outcome of the Georgia litigation will decide whether the Bainbridge project can proceed at all. The expansion of the Florida holding facility will show whether the company can build a working business while its flagship site remains tied up. And the finalization of the FDA's guidance on primate studies for monoclonal antibodies will signal how much long-term demand for research monkeys will remain.
For pharmaceutical companies, the episode shows primate supply remains a strategic vulnerability. For investors, it illustrates the risk of building long-lived capacity against a market regulators are deliberately reshaping.
Post a Comment